logo
welcome
Reuters

Reuters

Merck scraps two late-stage trials of cancer drug Keytruda

Reuters
Summary
Nutrition label

79% Informative

Merck has stopped two late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers.

The company has been seeking to test the drug in combination with other treatments.

The drug faces loss of patent protection at the end of the decade .

Merck: "Unmet needs remain across different types of cancer and stages of disease".

VR Score

90

Informative language

98

Neutral language

42

Article tone

formal

Language

English

Language complexity

65

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links